Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
Fiche publication
Date publication
février 2017
Journal
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel, Dr GUENOT Dominique, Pr ROHR Serge, Dr ROMAIN Benoit, Pr BRIGAND Cécile, Pr OLLAND Anne
Tous les auteurs :
Renaud S, Schaeffer M, Falcoz PE, Seitlinger J, Romain B, Voegeli AC, Legrain M, Reeb J, Santelmo N, Rohr S, Brigand C, Olland A, Guenot D, Massard G
Lien Pubmed
Mots clés
Aged, Antineoplastic Agents, administration & dosage, Bevacizumab, administration & dosage, Biomarkers, Tumor, genetics, Chemotherapy, Adjuvant, Colorectal Neoplasms, genetics, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lung Neoplasms, genetics, Male, Metastasectomy, Middle Aged, Mutation, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Proto-Oncogene Proteins B-raf, genetics, Proto-Oncogene Proteins p21(ras), genetics, Retrospective Studies
Référence
Eur J Cardiothorac Surg. 2017 Feb;51(2):255-262